Johnson & Johnson $JNJ Shares Purchased by Wealth Alliance LLC

Wealth Alliance LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.9% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 24,125 shares of the company’s stock after purchasing an additional 1,116 shares during the quarter. Wealth Alliance LLC’s holdings in Johnson & Johnson were worth $3,685,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. GFG Capital LLC acquired a new stake in Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth about $48,000. Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $52,000. Finally, Pandora Wealth Inc. acquired a new position in Johnson & Johnson in the first quarter valued at about $65,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. The Goldman Sachs Group raised their price target on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Finally, Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Trading Up 2.8%

NYSE:JNJ opened at $193.76 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The stock has a market cap of $466.83 billion, a P/E ratio of 18.70, a P/E/G ratio of 2.19 and a beta of 0.38. The stock has a 50-day simple moving average of $184.79 and a 200-day simple moving average of $169.31.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.